MedX Health Corp (MDXHF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MedX Health Corp (MDXHF) trades at $0.025 with AI Score 54/100 (Grade B). MedX Health Corp develops and markets skin screening tools and phototherapy devices. Market cap: $8.20M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MDXHF: MDXHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MDXHF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MDXHF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MedX Health Corp (MDXHF) Healthcare & Pipeline Overview
MedX Health Corp is a medical device and software company specializing in skin cancer screening and phototherapy. Its key product, SIAscopy, aids in early detection of suspicious moles and lesions, while its DermSecure platform expands access through telemedicine. The company operates in Canada, the US, and internationally.
What Is the Investment Thesis for MDXHF?
MedX Health Corp presents a compelling investment thesis centered on the growing demand for early skin cancer detection and the increasing adoption of telemedicine solutions. The company's DermSecure platform offers a scalable solution for remote dermatological assessments, addressing the shortage of dermatologists and improving access to care. With a market capitalization of $8.20M, MedX is positioned to capitalize on the expanding telemedicine market. Key value drivers include increasing DermSecure platform adoption, expanding its network of third-party locations, and strategic partnerships to broaden market reach. However, the company's negative profit margin of -1014.0% and reliance on OTC markets pose significant risks.
Based on FMP financials and quantitative analysis
MDXHF Key Highlights
Market capitalization of $8.20M, indicating a micro-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -3.43, reflecting current unprofitability but potential for future earnings growth.
- Gross margin of 33.6%, suggesting a reasonable ability to control production costs.
- Beta of 1.90, indicating higher volatility compared to the overall market.
- Operates DermSecure telemedicine platform, enabling remote skin assessments and expanding market reach.
Who Are MDXHF's Competitors?
MDXHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| BLOZF Cannabix Technologies Inc. | $0.36 | -5.41% | $44.1M | 51 |
| BSEM BioStem Technologies, Inc. | $3.35 | +6.19% | $56.8M | — |
| NICXF Nicox S.A. | $0.30 | +0.00% | $29.2M | 55 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDXHF's Key Strengths?
Proprietary SIAscopy technology for early skin cancer detection.
- DermSecure telemedicine platform expands access to dermatological expertise.
- Established presence in Canada, the United States, and international markets.
- Focus on a growing market with increasing demand for skin cancer screening.
What Are MDXHF's Weaknesses?
Negative profit margin and reliance on external funding.
- Limited brand recognition compared to larger medical device companies.
- Dependence on regulatory approvals for new products and market expansion.
- High beta indicates significant stock price volatility.
What Could Drive MDXHF Stock Higher?
Expansion of DermSecure platform into new geographic markets within the next 1-2 years.
- Strategic partnerships with dermatology clinics and healthcare providers to increase adoption of MedX's technologies.
- Development of new and improved skin screening technologies to enhance competitive advantage.
What Are the Key Risks for MDXHF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Negative profit margin and reliance on external funding pose financial sustainability risks.
- Competition from larger medical device companies with greater resources could erode market share.
- Changes in healthcare regulations and reimbursement policies could impact revenue.
- Technological advancements by competitors could render existing products obsolete.
What Are the Growth Opportunities for MDXHF?
- Expansion of DermSecure Platform: The DermSecure telemedicine platform presents a significant growth opportunity for MedX. By expanding its network of third-party locations and partnering with healthcare providers, MedX can increase the reach of its skin screening services. The global telemedicine market is projected to reach $400 billion by 2027, providing a substantial market for DermSecure. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with dermatology clinics, hospitals, and other healthcare organizations can accelerate the adoption of MedX's technologies. These partnerships can provide access to new markets and customer segments. The company can leverage these partnerships to integrate its solutions into existing healthcare workflows. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in regions with high skin cancer incidence rates, represents a significant growth opportunity. MedX can target countries with limited access to dermatological expertise and establish a presence through partnerships or direct sales. Timeline: 1-3 years.
- Product Development: Investing in the development of new and improved skin screening technologies can enhance MedX's competitive advantage. This includes exploring artificial intelligence and machine learning to improve the accuracy and efficiency of skin cancer detection. Timeline: 2-5 years.
- Increased Awareness: Launching marketing campaigns to increase awareness of skin cancer risks and the benefits of early detection can drive demand for MedX's products and services. This includes educating the public about the importance of regular skin checks and the availability of telemedicine solutions. Timeline: Ongoing.
What Are MDXHF's Competitive Advantages?
- Proprietary SIAscopy technology provides a competitive advantage in skin cancer screening.
- DermSecure telemedicine platform offers a scalable solution for remote dermatological assessments.
- Established presence in Canada, the United States, and international markets.
- Strong relationships with dermatology clinics and healthcare providers.
What Does MDXHF Do?
MedX Health Corp, established in 1999 and headquartered in Mississauga, Canada, is focused on developing, manufacturing, and marketing innovative medical devices and software for skin health assessment and therapeutic applications. The company's core technology revolves around SIAscopy, a non-invasive imaging technique that aids in the early detection of skin cancer by scanning moles and lesions. This technology is complemented by the DermSecure telemedicine platform, which enables remote dermatological assessments, connecting patients in remote locations with specialist physicians. MedX's product portfolio also includes phototherapeutic medical devices utilizing low-level laser and LED light energy for pain relief and tissue repair, targeting the rehabilitation market. These devices are marketed under various brand names, including SIAMETRICS, SIMSYS, and MoleMate. MedX Health operates in Canada, the United States, and internationally, seeking to expand access to dermatological expertise and improve skin cancer detection rates through its integrated technology solutions.
What Products and Services Does MDXHF Offer?
- Develops and manufactures SIAscopy devices for skin cancer screening.
- Offers phototherapeutic medical devices for pain relief and tissue repair.
- Operates the DermSecure telemedicine platform for remote dermatological assessments.
- Provides SIAMETRICS, SIMSYS, and MoleMate imaging solutions for mole and lesion evaluation.
- Connects patients with specialist physicians for remote skin assessments.
- Markets its products in Canada, the United States, and internationally.
How Does MDXHF Make Money?
- Sells SIAscopy devices and related software to dermatology clinics and healthcare providers.
- Generates revenue from DermSecure platform usage fees, charging for remote consultations and assessments.
- Markets phototherapeutic medical devices to rehabilitation centers and pain management clinics.
- Offers service contracts for device maintenance and support.
What Industry Does MDXHF Operate In?
MedX Health Corp operates within the medical device industry, specifically targeting the dermatology and telemedicine sectors. The global medical device market is experiencing steady growth, driven by technological advancements, an aging population, and increasing healthcare expenditure. The telemedicine market is also expanding rapidly, fueled by the need for remote patient monitoring and improved access to healthcare services. MedX competes with companies offering similar skin screening technologies and telemedicine platforms. Key competitors include AIRDF, BLOZF, BSEM, CRRVF, and NICXF.
Who Are MDXHF's Key Customers?
- Dermatology clinics and dermatologists.
- Hospitals and healthcare organizations.
- Rehabilitation centers and pain management clinics.
- Patients seeking skin cancer screening and remote dermatological assessments.
MedX Health Corp Financial Trajectory
MedX Health Corp (MDXHF) reported $178K in revenue for Q1 2026, reflecting 28.9% growth compared to the prior quarter. The company recorded a net loss of $1.2M, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, MDXHF averaged $-0.00 in diluted EPS.
Company Profile
MedX Health Corp operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO John Gevisser. MDXHF has traded publicly since 2008.
How MedX Health Corp Is Valued
MedX Health Corp carries a market capitalization of $8.20M, placing it in the micro-cap category. Relative to its peer group, MDXHF's quantitative score of 54/100 is roughly in line with the peer average of 57/100.
Key Financial Metrics
Return on equity for MedX Health Corp stands at 62.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -72.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -105.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
MedX Health Corp's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project MedX Health Corp revenue of about $3.4M for fiscal 2026, with EPS near $-0.02.
MDXHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MedX's growth potential, indicating that those closest to the company believe in its future.
- Community sentiment has shifted positively, with discussions highlighting MedX's innovative approach to telemedicine and skin health solutions.
- Analysts have noted increasing interest in the telehealth sector, positioning MedX as a potential leader in this expanding market.
- The company's recent partnerships with healthcare providers have strengthened its market presence and enhanced its credibility.
Bear Case
- Despite recent positive sentiment, some investors remain skeptical about MedX's ability to scale its operations effectively amid competition.
- Concerns about the overall economic environment may lead to cautious spending in the healthcare sector, impacting MedX's growth prospects.
- There have been mixed reviews regarding the effectiveness of MedX's products, which could affect consumer trust and adoption rates.
- Market volatility and regulatory challenges in the telehealth space could pose risks to MedX's operational stability and future performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $178,207 | -$1M | -$0.0038 |
| Q4 2025 | $138,287 | -$2M | -$0.01 |
| Q3 2025 | $135,268 | -$1M | -$0.0043 |
| Q2 2025 | $88,512 | -$1M | -$0.0045 |
Based on FMP financials and quantitative analysis
MDXHF Latest News
-
MedX Health Launches SkinSecure™ to Bring Direct, Non-Invasive, Objective Biological Measurement to Skin Health Research
Yahoo! Finance: MDXHF News · Jun 26, 2026
MDXHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDXHF.
Price Targets
Wall Street price target analysis for MDXHF.
MDXHF MoonshotScore
What does this score mean?
The MoonshotScore rates MDXHF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Gevisser
CEO
John Gevisser is the Chief Executive Officer of MedX Health Corp. His background includes extensive experience in the medical device and healthcare industries. He has held various leadership positions in sales, marketing, and business development. Gevisser's expertise lies in driving revenue growth, expanding market share, and building strategic partnerships. He is focused on executing MedX's growth strategy and delivering value to shareholders.
Track Record: Since becoming CEO, John Gevisser has focused on expanding the DermSecure platform and increasing its adoption among healthcare providers. He has also overseen the development of new skin screening technologies and the expansion into new geographic markets. Under his leadership, MedX has strengthened its partnerships with dermatology clinics and hospitals.
MDXHF OTC Market Information
The OTC Other tier, where MDXHF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements. This contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in MDXHF.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- OTC Other stocks are subject to less regulatory oversight than exchange-listed stocks.
- Potential for fraud or manipulation is higher in the OTC market.
- Liquidity risk can make it difficult to exit positions quickly.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- MedX Health Corp has been in operation since 1999, suggesting a degree of stability.
- The company has developed and markets medical devices and software, indicating a tangible business.
- MedX operates the DermSecure telemedicine platform, showing innovation in healthcare delivery.
- The company has a CEO and management team in place.
- MedX has a gross margin of 33.6%.
What Investors Ask About MedX Health Corp (MDXHF) — Healthcare
What does the AI Score mean for MDXHF?
MDXHF holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. MedX Health Corp develops and markets skin screening tools and phototherapy devices. Its DermSecure platform facilitates remote assessment of moles and lesions, positioning it in the telemedicine …
What does MedX Health Corp do?
MedX Health Corp is a medical device and software company focused on skin cancer screening and phototherapy. It develops, manufactures, and markets the SIAscopy device, which aids in the early detection of suspicious moles and lesions. The company also operates the DermSecure telemedicine platform, enabling remote dermatological assessments.
What do analysts say about MDXHF stock?
As of 2026-03-16, there is no readily available analyst consensus on MDXHF stock due to its OTC listing and limited coverage. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include market capitalization, P/E ratio, and gross margin. Growth considerations include the expansion of the DermSecure platform and strategic partnerships.
What are the main risks for MDXHF?
The main risks for MedX Health Corp include its negative profit margin and reliance on external funding, which pose financial sustainability challenges. Competition from larger medical device companies with greater resources could erode market share. Changes in healthcare regulations and reimbursement policies could impact revenue. Technological advancements by competitors could render existing products obsolete. Additionally, as an OTC-listed stock, MDXHF is subject to greater liquidity and regulatory risks.
What are the key factors to evaluate for MDXHF?
MedX Health Corp (MDXHF) holds an AI score of 54/100 (moderate). MedX Health Corp presents a compelling investment thesis centered on the growing demand for early skin cancer detection and the increasing adoption of telemedicine solutions. Not financial advice.
How frequently does MDXHF data refresh on this page?
MDXHF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MDXHF's recent stock price performance?
MedX Health Corp (MDXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SIAscopy technology for early skin cancer detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDXHF overvalued or undervalued right now?
MedX Health Corp (MDXHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MDXHF before investing?
Before investing in MedX Health Corp (MDXHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.